Marc Carrier profile picture

Contact Information

Marc Carrier, MD, MSc, FRCPC
613-737-8899, ext 73034

ORCID logo

Marc Carrier

Senior Scientist, Inflammation & Chronic Disease
Ottawa Hospital Research Institute
Chief, Division of Hematology, Department of Medicine
The Ottawa Hospital
Professor, Department of Medicine
University of Ottawa

Research Interests

Venous thromboembolic disease and cancer, including cancer screening, prevention and management

Brief Biography

Marc Carrier, MD, MSc, FRCPC, is Head of the Division of Hematology in the Department of Medicine at The Ottawa Hospital, a Professor in the Faculty of Medicine, University of Ottawa and a Senior Scientist in the Clinical Epidemiology Program of The Ottawa Hospital Research Institute. He holds a Tier 1 Research Chair in Venous Thromboembolism and Cancer from the University of Ottawa and New Investigator Award from the Heart and Stroke Foundation of Canada. In 2015 he was the recipient of the prestigious Dr. Michel Chrétien Researcher of the Year Award for his study published in the New England Journal of Medicine that improves care for VTE patients around the world.

Clinical research is focused in venous thromboembolic disease and cancer, including cancer screening, prevention and management. Is currently the Principal Investigator on four peer-reviewed clinical trials (Heart and Stroke Foundation (2) and Canadian Institutes of Health Research (2) ) and numerous industry sponsored trials. He has published important systematic reviews and has had multiple international speaking invitations to speak on the topics of cancer and thrombosis.

Selected Publications

Carrier M, Abou-Nassar K, Mallick R, Tagalakis V, Shivakumar S, Schattner A, Kuruvilla P, Hill D, Spadafora S, Marquis K, Trinkaus M, Tomiak A, Lee AYY, Gross PL, Lazo-Langner A, El-Maraghi R, Goss G, Le Gal G, Stewart D, Ramsay T, Rodger M, Witham D, Wells PS; AVERT Investigators. Apixaban to Prevent Venous Thromboembolism in Patients with Cancer. N Engl J Med. 2019 Feb 21;380(8):711-719

Carrier M, Lazo-Langner A, Shivakumar S, Tagalakis V, Zarychanski R, Solymoss S, Routhier N, Douketis J, Danovitch K, Lee AY, Le Gal G, Wells PS, Corsi DJ, Ramsay T, Coyle D, Chagnon I, Kassam Z, Tao H, Rodger M for the SOME Investigators. Screening for Occult Cancer in Unprovoked Venous Thromboembolism. N Engl J Med. 2015 Aug 20;373(8):697-704.

Castellucci LA, Cameron C, Le Gal G, Rodger MA, Coyle D, Wells PS, Clifford T, Gandara E, Wells G, Carrier M. Clinical and safety outcomes associated with treatment of acute venous thromboembolisme: A systematic review and meta-analysis. JAMA. 2014 Sep;312(11):1122.1135.

Castellucci LA, Cameron C, Le Gal G, Rodger MA, Coyle D, Wells PS, Clifford T, Gandara E, Wells G, Carrier M. Efficacy and safety outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism: systematic review and network meta-analysis. BMJ 2013;347:f5133.

Carrier M, Le Gal G, Wells P, Rodger M. Systematic review: Case-fatality rates of recurrent venous thromboembolism and major bleeding events among patients treated for venous thromboembolism. Ann Intern Med. 2010 May;152(9):578-589.

Carrier M, Le Gal G, Wells PS, Fergusson D, Ramsay T, Rodger MA. Systematic review: the Trousseau syndrome revisited: should we screen extensively for cancer in patients venous thromboembolism? Ann Intern Med. 2008 Sept 2;149(5):323-33.

Diseases, conditions and populations of interest

Research and clinical approaches